Michael Douglas

Program Manager
Department of Clinical Pharmacy
Douglas
[email protected]
Phone: +1 415 502-4025
521 Parnassus Avenue, Rm 3504
UCSF Box 0622
San Francisco, CA 94117
United States

Links

UCSF Profiles

Affiliations

Department committees and service

DEI-AR Committee, 2023, Department of Clinical Pharmacy

What I do

I serve as the program manager in the UCSF Department of Clinical Pharmacy in the laboratory of Akinyemi Oni-Orisan, PharmD, PhD. As program manager, I have a leadership role in several grants, research and research development, program management, and publication. I’ve led and co-authored many publications in the field of genomic medicine and molecular diagnostics.

My research focuses on new technologies and equitable implementation in healthcare, focusing on precision medicine, cardiovascular disease, cancer, and diverse populations. My research spans a variety of disciplines, including clinical and social sciences, in the academic, government, and industry sectors. I have extensive expertise in genomic laboratory medicine, evidence-based reviews of molecular-based testing, personalized medicine, and research program management.

I have been working with researchers in the precision medicine field for over 23 years in varying organizations, including the Centers for Disease Control and Prevention’s Office of Genomics and Precision Public Health, Blue Cross Blue Shield Association’s Technical Evaluation Center, and Bayer Diagnostics.

Professional background

Degrees

MS, Molecular Biology, SUNY College of Environmental Science and Forestry, 1997

Biography

I serve as the program manager in the UCSF Department of Clinical Pharmacy in the laboratory of Akinyemi Oni-Orisan, PharmD, PhD. As program manager, I have a leadership role in several grants, research and research development, program management, and publication. I’ve led and co-authored many publications in the field of genomic medicine and molecular diagnostics.

My research focuses on new technologies and equitable implementation in healthcare, focusing on precision medicine, cardiovascular disease, cancer, and diverse populations. My research spans a variety of disciplines, including clinical and social sciences, in the academic, government, and industry sectors. I have extensive expertise in genomic laboratory medicine, evidence-based reviews of molecular-based testing, personalized medicine, and research program management.

I have been working with researchers in the precision medicine field for over 23 years in varying organizations, including the Centers for Disease Control and Prevention’s Office of Genomics and Precision Public Health, Blue Cross Blue Shield Association’s Technical Evaluation Center, and Bayer Diagnostics.

Research keywords

  • Payer Coverage Decisions
  • health policy
  • Clinical decision support
  • patient-reported outcome measures
  • patient generated health data
  • next-generation sequencing
  • Polygenic Risk Score
  • Molecular Testing
  • Cardiovascular Disease
  • big data
  • consumer health informatics
  • personalized medicine
  • precision medicine
  • cancer
  • Reimbursement
  • Genetics/Genomics
  • electronic health records (EHR)
  • Physician's Role
  • Technology Assessment, Biomedical
  • precision medicine
  • Genetic Testing
  • Health Expenditures
  • Exome
  • genomics
  • Circulating Tumor DNA
  • Clinical Laboratory Services
  • High-Throughput Nucleotide Sequencing
  • Direct-To-Consumer Screening and Testing
  • Insurance Coverage
  • Insurance, Health, Reimbursement
  • policy
  • comparative effectiveness research

Publications

Yee SW, Haldar T, Kvale M, Yang J, Douglas MP, Oni-Orisan A. SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study. medRxiv. 2023 Dec 03.
Chen C, Douglas MP, Ragavan MV, Phillips KA, Jansen JP. Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis. medRxiv. 2023 Oct 28.
Jansen JP, Ragavan MV, Chen C, Douglas MP, Phillips KA. The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis. Value Health. 2023 Dec; 26(12):1697-1710.
Julia R Trosman, Christine B Weldon, Allison W Kurian, Mary M Pasquinelli, Sheetal M Kircher, Nikki Martin, Michael P Douglas, Kathryn A Phillips. Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy. . 2023 Jun 20; 1(1).
Douglas MP, Ragavan MV, Chen C, Kumar A, Gray SW, Blakely CM, Phillips KA. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment. J Natl Compr Canc Netw. 2023 06; 21(6):609-616.e4.
Williamson KM, Butler M, Elton B, Taylor J, Islam F, Douglas MP, Kirk MD, Durrheim DN. Transmission of SARS-CoV-2 Delta variant from an infected aircrew member on a short-haul domestic flight, Australia 2021. J Travel Med. 2022 12 27; 29(8).
Weldon CB, Trosman JR, Liang SY, Douglas MP, Scheuner MT, Kurian A, Schaa KL, Roscow B, Erwin D, Phillips KA. Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes. J Genet Couns. 2022 12; 31(6):1394-1403.
Douglas MP, Kumar A. Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review. J Pers Med. 2022 Apr 01; 12(4).
Deverka PA, Douglas MP, Phillips KA. Multicancer Screening Tests: Anticipating And Addressing Considerations For Payer Coverage And Patient Access. Health Aff (Millwood). 2022 03; 41(3):383-389.
Arias JJ, Lin GA, Tyler AM, Douglas MP, Phillips KA. Geriatricians' Perspectives on the Multiple Dimensions of Utility of Genetic Testing for Alzheimer's Disease: A Qualitative Study. J Alzheimers Dis. 2022; 90(3):1011-1019.
Phillips KA, Trosman JR, Douglas MP, Gelb BD, Ferket BS, Hindorff LA, Slavotinek AM, Berg JS, Russell HV, Devine B, Greve V, Smith HS. US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). Genet Med. 2022 01; 24(1):238-244.
Douglas MP, Lin GA, Trosman JR, Phillips KA. Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants. J Community Genet. 2022 Feb; 13(1):75-80.
Christine B. Weldon, Su-Ying Liang, Kathryn A. Phillips, Michael P. Douglas, Maren Theresa Scheuner, Allison W. Kurian, Kendra Schaa, Breanna Roscow, Deanna Erwin, Julia R. Trosman. Multicancer hereditary syndrome testing: Genetic counselors’ perspectives. Journal of Clinical Oncology. 2021 Oct 1; 39(28_suppl):106-106.
Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA. Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. J Genet Couns. 2022 02; 31(1):130-139.
Christine B. Weldon, Su-Ying Liang, Kathryn A Phillips, Michael P Douglas, Maren Theresa Scheuner, Allison W. Kurian, Kendra Schaa, Breanna Roscow, Deanna Erwin, Julia Rachel Trosman. Multicancer hereditary syndrome testing: Genetic counselors’ perspectives. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):10594-10594.
Scheuner MT, Douglas MP, Sales P, Ackerman SL, Phillips KA. Laboratory business models and practices: implications for availability and access to germline genetic testing. Genet Med. 2021 09; 23(9):1681-1688.
Grace Lin, Maren Scheuner, Julia Trosman, Paloma Sales, Sara Ackerman, Michael Douglas, Christine Weldon, Allison Kurian, Kathryn Phillips. OP511 Financing of germline testing: implications for availability and access. Molecular Genetics and Metabolism. 2021 Apr 1; 132:s330-s331.
Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. Availability and funding of clinical genomic sequencing globally. BMJ Glob Health. 2021 02; 6(2).
Arias JJ, Tyler AM, Douglas MP, Phillips KA. Private payer coverage policies for ApoE-e4 genetic testing. Genet Med. 2021 04; 23(4):614-620.
Phillips KA, Douglas MP, Marshall DA. Expanding Use of Clinical Genome Sequencing and the Need for More Data on Implementation. JAMA. 2020 11 24; 324(20):2029-2030.
K. Phillips, S. Wordsworth, D. Regier, D. Marshall, M.P. Douglas, J. Buchanan. PCV3 Global Landscape of Clinical Genomic Sequencing: Who, Where, and How?. Value in Health Regional Issues. 2020 Sep 1; 22:s26.
Douglas MP, Gray SW, Phillips KA. Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019. J Natl Compr Canc Netw. 2020 07; 18(7):866-872.
Deverka PA, Douglas MP, Phillips KA. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions. Value Health. 2020 05; 23(5):540-550.
Trosman JR, Douglas MP, Liang SY, Weldon CB, Kurian AW, Kelley RK, Phillips KA. Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019. Value Health. 2020 05; 23(5):551-558.
Trosman JR, Weldon CB, Slavotinek A, Norton ME, Douglas MP, Phillips KA. Perspectives of US private payers on insurance coverage for pediatric and prenatal exome sequencing: Results of a study from the Program in Prenatal and Pediatric Genomic Sequencing (P3EGS). Genet Med. 2020 02; 22(2):283-291.
Phillips KA, Trosman JR, Douglas MP. Emergence of Hybrid Models of Genetic Testing Beyond Direct-to-Consumer or Traditional Labs. JAMA. 2019 06 25; 321(24):2403-2404.
Phillips KA, Trosman JR, Weldon CB, Douglas MP. New Medicare Coverage Policy for Next-Generation Tumor Sequencing: A Key Shift in Coverage Criteria With Broad Implications Beyond Medicare. JCO Precis Oncol. 2018; 2.
Phillips KA, Douglas MP. The Global Market for Next-Generation Sequencing Tests Continues Its Torrid Pace. J Precis Med. 2018 Oct; 4.
Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips KA. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genet Med. 2019 01; 21(1):152-160.
Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Aff (Millwood). 2018 05; 37(5):710-716.
Phillips KA, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science. 2018 Apr 20; 360(6386):278-279.
Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D, MedSeq Project. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018 12; 20(12):1544-1553.
Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2018 01; 20(1):165.
Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas MP, Phillips KA. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. Int J Technol Assess Health Care. 2017 Jan; 33(4):534-540.
Phillips KA, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 07 12; 35(7):614-617.
Marshall DA, MacDonald KV, Robinson JO, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips KA. The price of whole-genome sequencing may be decreasing, but who will be sequenced? Per Med. 2017 May; 14(3):203-211.
Phillips KA, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017 10; 19(10):1081-1091.
Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips KA. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 02; 15(2):219-228.
Phillips KA, Douglas MP, Trosman JR, Marshall DA. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017 01; 20(1):47-53.
Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017 01; 20(1):40-46.
Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, Phillips KA. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017 05; 19(5):559-567.
Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips KA. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2016 12; 18(12):1295-1302.
Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips KA. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015 Sep; 33(9):900-2.
Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med. 2016 Feb; 18(2):111-6.
Julia Rachel Trosman, Christine B. Weldon, Allison W. Kurian, Michael P Douglas, Robin Kate Kelley, Kathryn A Phillips. Addressing lack of US insurance coverage of Cancer Hereditary Multiplex Testing (CHMT). Journal of Clinical Oncology. 2015 May 20; 33(15_suppl):e17515-e17515.
D.A. Marshall, J.M. Gonzalez, F.R. Johnson, A. Pugh, K.V. MacDonald, M.P. Douglas, K.A. Phillips. PND45 What are people willing to pay for whole genome sequencing information?. Value in Health. 2015 May 1; 18(3):a285-a286.
Phillips KA, Ladabaum U, Pletcher MJ, Marshall DA, Douglas MP. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genet Med. 2015 Apr; 17(4):314-5.
Garfeld S, Douglas MP, MacDonald KV, Marshall DA, Phillips KA. Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Per Med. 2015 Jan 01; 12(1):13-22.
Phillips KA, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014 Jul; 33(7):1246-53.
Dotson WD, Douglas MP, Kolor K, Stewart AC, Bowen MS, Gwinn M, Wulf A, Anders HM, Chang CQ, Clyne M, Lam TK, Schully SD, Marrone M, Feero WG, Khoury MJ. Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clin Pharmacol Ther. 2014 Apr; 95(4):394-402.
Clyne M, Schully SD, Dotson WD, Douglas MP, Gwinn M, Kolor K, Wulf A, Bowen MS, Khoury MJ. Horizon scanning for translational genomic research beyond bench to bedside. Genet Med. 2014 Jul; 16(7):535-8.
Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014 Mar; 16(3):251-7.
Palomaki GE, Melillo S, Marrone M, Douglas MP. Use of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review. Genet Med. 2013 Aug; 15(8):600-11.
Palomaki GE, Melillo S, Neveux L, Douglas MP, Dotson WD, Janssens AC, Balkite EA, Bradley LA. Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies--a targeted evidence-based review. Genet Med. 2010 Dec; 12(12):772-84.
Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med. 2009 Jan; 11(1):21-34.
Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO, EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009 Jan; 11(1):3-14.
Schinsky MF, Morey RE, Steigerwalt AG, Douglas MP, Wilson RW, Floyd MM, Butler WR, Daneshvar MI, Brown-Elliott BA, Wallace RJ, McNeil MM, Brenner DJ, Brown JM. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates. Int J Syst Evol Microbiol. 2004 Sep; 54(Pt 5):1653-1667.
Daneshvar MI, Hollis DG, Weyant RS, Steigerwalt AG, Whitney AM, Douglas MP, Macgregor JP, Jordan JG, Mayer LW, Rassouli SM, Barchet W, Munro C, Shuttleworth L, Bernard K. Paracoccus yeeii sp. nov. (formerly CDC group EO-2), a novel bacterial species associated with human infection. J Clin Microbiol. 2003 Mar; 41(3):1289-94.
Daneshvar MI, Douglas MP, Weyant RS. Cellular fatty acid composition of Lautropia mirabilis. J Clin Microbiol. 2001 Nov; 39(11):4160-2.
Teixeira LM, Carvalho MG, Espinola MM, Steigerwalt AG, Douglas MP, Brenner DJ, Facklam RR. Enterococcus porcinus sp. nov. and Enterococcus ratti sp. nov., associated with enteric disorders in animals. Int J Syst Evol Microbiol. 2001 Sep; 51(Pt 5):1737-1743.
Daneshvar MI, Hollis DG, Steigerwalt AG, Whitney AM, Spangler L, Douglas MP, Jordan JG, MacGregor JP, Hill BC, Tenover FC, Brenner DJ, Weyant RS. Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies. J Clin Microbiol. 2001 May; 39(5):1819-26.
Douglas MP, Rogers SO. DNA damage caused by common cytological fixatives. Mutat Res. 1998 Jun 05; 401(1-2):77-88.